The global home healthcare market is projected to reach USD 383.0 Billion by 2028 from USD 250.0 Billion in 2023, at a CAGR of 8.9% during the forecast period. The primary drivers of the home healthcare market’s growth are the aging population and the growing need for cost-effective healthcare delivery brought on by rising healthcare expenses.

The home healthcare market is divided into three segments based on products: mobility care items, therapeutic products, and products for testing, screening, and monitoring. By 2022, the market for home healthcare goods was led by the therapeutic sector. The need for home healthcare treatment equipment has increased due to the rising prevalence of chronic illnesses such kidney failure and respiratory infections.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=696

Home Healthcare Market by Product (Dialysis Equipment, Ventilators, HIV Test Kits, Hearing Aids, Activity Monitors), Service (Skilled Nursing, Infusion Therapy, Palliative Care), Indication (Cancer, Wound Care, Diabetes), & Region- Global Forecast to 2028

The skilled nursing, rehabilitation therapy, hospice & palliative care, unskilled care, respiratory therapy, infusion treatment, and prenatal care services are the several service categories that make up the home healthcare market. In 2022, skilled nursing services held the most market share for home healthcare. Getting expert medical care at home can be a more consoling option than being in a hospital, assisted living facility, or nursing home. Over the course of the projection period, the market’s expansion is anticipated to be supported by the excellent insurance coverage for skilled nursing services.

The home healthcare market is divided into indications such as wound care, diabetes, cancer, respiratory illnesses, mobility disorders, cardiovascular diseases & hypertension, pregnancy, hearing abnormalities, and other indications. In 2022, the home healthcare market’s greatest share belonged to the other indications category. HIV infections are on the rise and sleep difficulties are highly prevalent, which is the main reason for this segment’s size.

Home healthcare markets throughout the world are divided into four regions: North America, Europe, Asia Pacific, and the Rest of the World. North America led the world’s home healthcare industry in 2022, with Europe following closely behind. The increased prevalence of chronic illnesses and high healthcare costs are the main reasons for North America’s significant market share in the global economy. On the other hand, throughout the course of the forecast period, the Asia Pacific market is anticipated to develop at the highest CAGR. The aging population and technology improvements are the main drivers of growth in the Asia Pacific home healthcare market.

Major Players:

Fresenius SE & Co. KGaA (Germany), Linde, Plc (Ireland), F.Hoffmann-La Roche, Ltd. (Switzerland), A&D Company, Limited (Japan), Bayada Home Health Care (US), Invacare Corporation (US), Abbott (US), Amedisys (US), ResMed, Inc. (US), LHC Group, Inc. (US), Omron Corporation (Japan), Koninklijke Philips N.V. (Netherlands), GE Healthcare (US), Drive Devilbiss Healthcare (UK), Sunrise Medical (Germany), Roma Medical (UK), Caremax Rehabilitation Equipment Co., Ltd. (China), Vitalograph (UK), Advita Pflegedienst Gmbh (Germany), Renafan Gmbh (Germany), Contec Medical Systems Co., Ltd. (China), B. Braun Melsungen Ag (Germany), Baxter International, Inc. (US), Medline Industries, Inc. (US), and Advin Health Care (India)

Recent Developments of Home Healthcare Industry:

• In August 2022, Fresenius Medical Care North America (FMCNA) acquired InterWell Health Brand (US) to expertise in kidney care value-based contracting and performance.
• In August 2022, Contessa (US) partnered with Mount Sinai Health System (US) offers a full continuum of home-based care that includes home health, hospitalization at home, rehabilitation at home (in lieu of care at a skilled nursing facility) and palliative care at home.
• In July 2022, Invacre Corporation (US) introduced Next Generation e-fix eco Power Assist Device to Transform the Manual Wheelchair.

The global endoscopy equipment market is projected to reach USD  46.2 billion by 2029 from USD  32.3 billion in 2024, at a CAGR of 7.4%.

The global endoscopy equipment market is experiencing substantial growth due to many driving factors, including surging requirement for endoscopy to diagnose and treat target diseases, increasing investments, funds, and grants by governments and other organizations worldwide, growing focus of hospitals to invest in technology advanced endoscopy instruments and expand endoscopy units, ongoing advancements in endoscopic technologies to ensure patient safety and achieve more accurate treatments, rising incidence of IBD and CRC that require endoscopy procedures. Drivers such as Increasing preference for minimally invasive surgeries, adoption of single-use endoscopy instruments to prevent infectious diseases and offer increased efficiency and safety, and rising focus of medical specialities to shift from manual to automated endoscopy reprocessing are also contributing towards the overall growth of the global endoscopy equipment market.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=689

Endoscopy Equipment Market by Product (Endoscope (Flexible, Disposible, Rigid, Capsule, Robot-assisted), Visualization Systems (Video Converters, Recorders, Processors)), Application, End User, and Region – Global Forecast to 2029

In this report, the endoscopy equipment market is segmented into product type, application type, end user, and region.

Based on product type, the endoscopy equipment market is divided into endoscopes, visualization systems, other endoscopy equipment, and accessories. As of 2023, the accessories segment accounted the third largest share in the global endoscopy equipment market.The market share can be attributed to the factors that there are a side variety of accessories designed for specific procedures and functionalities and they are compatible with various models from the manufacturers..

Based on the type of applications, the endoscopy equipment market includes segments such as gastrointestinal endoscopy, laparoscopy, arthroscopy, obstetrics/gynecology endoscopy, urology endoscopy, bronchoscopy, mediastinoscopy, ENT endoscopy, and other specialized applications. Among these, the arthroscopy segment accounted the fourth largest share of the overall endoscopy equipment market in 2023. This dominance is primarily attributed to demographic shifts, particularly the aging population in key regions like the US, China, Japan, and India. Additionally, the increased prevalence of joint injuries like ligament tears, meniscus damange, and rotator cuff injuriesamong younger adults has heightened awareness about the importance of  arthroscopy, contributing to the segment’s significant growth rate.

Based on end users, the endoscopy equipment market is segmented into hospitals, ambulatory surgery centers/clinics and other end user. The other end user segment accounted for the third largest share in  the endoscopy equipment market in 2023. This dominance can be attributed to several driving factors. Diagnostic Laboratories, Research Institutions has nowadays started to implement new technologies and advanced procedures. Additionally, the increasing prevalence of complex medical conditions requiring diagnostic  endoscopic procedures further amplifies the demand for such equipment within diagnostic centers, solidifying their position in this market.

Based on the regions, in 2023, North America emerged as the dominant region in the endoscopy equipment market, followed by Europe, APAC, Latin America and Middle East and Africa. This leadership position is owed to substantial investments made by hospitals towards procuring advanced endoscopic equipment, coupled with a strong emphasis on research aimed at refining endoscopy techniques. Additionally, favorable reimbursement policies for endoscopic procedures in the US and the adoption of innovative funding models by  hospitals in Canada further bolstered the region’s prominence.

Prominent players in the endoscopy equipment market include Olympus Corporation (Japan), KARL STORZ SE & Co. KG (Germany), Boston Scientific Corporation (US), JOHNSON & JOHNSON (US), Stryker Corporation (US), Medtronic, plc (Ireland), Fujifilm Holdings Corporation (Japan), HOYA Corporation (Japan), Nipro Corporation (Japan), Smith & Nephew plc (UK), Intuitive Surgical, Inc. (US)

Recent Developments of Endoscopy Equipment Industry:

• In November 2023, Olympus Corporation launched the EVIS X1, an advanced endoscopy system in the existing product portfolio of the company..
• In September 2023, Stryker launched, 1788, a minimally invasive surgical camera, offering more vibrant image with balanced lighting.
• In January 2022, The Johnson & Johnson Medical Devices Companies (JJMDC) collaborated with Microsoft Corporation Inc, (US) to enable and expand JJMDC’s secure and compliant digital surgery ecosystem.

The global radiotherapy market is valued at USD 6.9 billion in 2023 and is expected to reach USD 8.8 billion by 2028, at a CAGR of 5.0% during the forecast period.

The expanding prevalence of cancer worldwide and the rising aging population has increased the demand for advanced and non-invasive cancer treatment. According to National Institute of Health (NIH), approximately 1,958,310 new cancer cases are expected to be registered in US by end of 2023.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=567

Radiotherapy Market by Type (Product, Service), Technology(MRI LINAC, Stereotactic, Particle Therapy, Cobalt-60 Teletherapy), Procedure (IMRT, IGRT, 3D-CRT, LDR, HDR), Application (Prostate, Breast, Lung), End User (Hospital) – Global Forecast to 2028

Rising technological advancements in radiotherapy systems and software are playing a significant role in offering precise and personalized cancer treatment. Additionally, investments in oncology research activities by public & private organizations and initiatives by government to enhance the accessibility of radiotherapy devices are likely to contribute towards the significant  growth of market during the forecast period. However, high cost associated with device procurement , limited financial budget, lack of health insurance coverage and inadequate healthcare infrastructure in low-income countries are likely to hinder the growth of radiotherapy market during the forecast period.

On the basis of type, the radiotherapy market is segmented into products and software & services. The products segment accounted for the largest share of radiotherapy market in 2023. Whereas the software & services segment is anticipated to register a significant growth rate from 2023-2028. This is attributed to the adoption of treatment planning softwares allowing more precise and optimized radiation dose delivery.

On the basis of technology, the radiotherapy market is segmented into external beam radiotherapy (further divided into linear accelerators, particle therapy systems, and conventional cobalt-60 teletherapy units, internal beam radiotherapy/brachytherapy (further segmented into seeds, applicators, after loaders, and IORT systems), and systemic radiotherapy products (including includes iobenguane (I-131), samarium-153, rhenium-186, and other radioisotopes (Yttrium-90, Radium-223, Phosphorous-32, and Radio-labelled antibodies, among others).

In 2022, linear accelerators, a sub-segment of external beam radiotherapy segment accounted for the largest market This is attributed to the increased capabilities of LINAC in delivering effective radiation dosage, growing usage of LINAC across developed and developing nations, growing awareness about the advancements associated with LINAC systems.

Based on end user, the radiotherapy market has been segmented into hospitals and independent radiotherapy centers. The hospitals segment accounted for the largest share of the radiotherapy market in 2023. This is attributed to the rising number of cancer patients undergoing radiotherapy treatment in hospitals and  budget allocation implemented government in developing nation with an aim to  enhance healthcare infrastructure, including the upgrading of radiotherapy equipment in hospitals.

The global radiotherapy market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest share of the radiotherapy market in 2022, followed by Europe. The larger share of North America is attribute to the strong adoption of advanced radiotherapy technology, presence of market players and favorable reimbursement policy in the region. The radiotherapy market in Asia Pacific is anticipated to experience significant growth opportunities in coming years owing to the government support for the development and commercialization of advanced radiotherapy devices , increased healthcare infrastructure, and rising number of cancer patients propelling demand for radiotherapy services across Asia Pacific Countries

the radiotherapy market was dominated by Siemens Healthineers AG (Germany), Varian Medical Systems, Inc. (US), Elekta (Sweden) Accuray Incorporated (US), IBA (Belgium), ViewRay Technologies, Inc. (US), Hitachi Ltd. (Japan), iCAD, Inc. (US), IsoRay, Inc. (US), , among others.

Recent Developments of Radiotherapy Industry

• In October 2023, Accuray incorporated received approval of Tomo C radiation therapy system by the Chinese National Medical Products Administration (NMPA).
• In July 2023, IBA entered into partnership with Apollo Proton Cancer Centre (APCC) (India) to provide training to Oncologist on proton beam therapy
• In April 2022, Elekta and GE Healthcare entered into a global commercial collaboration agreement in the field of radiation oncology, enabling them to provide hospitals a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy

The global mass spectrometry market is projected to reach USD 7.8 billion by 2028 from USD 5.4 billion in 2023, growing at a CAGR of 7.5% during the forecast period. The growth of the market is largely driven by the global rise in growing focus on the quality of food products, pollution control, environmental testing and increase in crude and shale gas production. Furthermore, the increasing spending on pharmaceutical R&D across the globe is anticipated to further propel market growth.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=437

Mass Spectrometry Market by Product (Instrument (Triple Quadrupole, Q-TOF, FTMS, Quadrupole, TOF), Services), Sample Preparation (LC-MS, GC-MS), Application (Omics, Clinical, Environmental), End User (Pharma, Academia, F&B) & Region – Forecasts to 2028

Based on the product, the mass spectrometry is segmented into instrument and software & services. During the forecast period, instrument is expected to dominate the mass spectrometry market. The growth of mass spectrometry instruments will be driven by the procedural benefits offered by LC-MS and triple-quadrapole mass spectrometer.

Based on sample preparation technique, the mass spectrometry is segmented into GC-MS, LC-MS, ICP-MS, and others. During the forecast period, LC-MS are expected to dominate the mass spectrometry market. The growth is attributed to its several analytical advantages such as higher accuracy, improved lower detection limits and also its broad applicability to a wide range of rigorous demands of the analytical market.

Based on application, the mass spectrometry market is segmented into OMICS research, drug discovery, environmental testing, food testing, pharma-biopharma manufacturing, clinical diagnostics, applied industries, and other applications. During the forecast period, the OMICS research segment is estimated to hold the largest market share of the mass spectrometry market. The advancements in biological research in proteomics and genomics being the major driver for growth. The segment includes life science related research like Genomics, Proteomics and Metabolomics.

The mass spectrometry market covers five key geographies—North America, Europe, Asia Pacific, Latin America and Middle East. The market in North America accounted for the largest share of market in 2022. The large share of the market can be attributed to the strong presence of major pharmaceutical companies and the large number of life science research studies conducted in the region. Europe is expected to account for the second-largest share of the global mass spectrometry market. Factors such as the flourishing biotechnology industry and favourable R&D scenarios are driving the growth of the mass spectrometry market in Europe.

The mass spectrometry business is very competitive, with both established companies and newcomers competing for the same market share. As of 2022, the key players operating in the global mass spectrometry market are SCIEX AB (US), Thermo Fisher Scientific (US), Agilent Technologies (US), Waters Corporation (US), PerkinElmer Inc. (US), Shimadzu Corporation (Japan) and Bruker Corporation (US) among others.

Recent Developments of Mass Spectrometry Industry

• In January 2022, Thermo Fisher and Symphogen extended their collaborative partnership with aim to deliver workflows for simplified characterization and quality monitoring of complex therapeutic proteins using the Thermo Scientific Q Exactive Plus Orbitrap LC-MS/MS system.
• In February 2023, SCIEX announced collaboration with HighRes Biosolutions to bring customizable automation solutions powered by Cellario software, which would add automation benefits to the Echo MS system.
• In February 2022, Waters Corporation acquired Charge Detection Mass Spectrometry technology assets and intellectual property rights of Megadalton Solutions, Inc., to broaden its application in Cell and Gene Therapy.
• In September 2022, Agilent Technologies partnered with MOBILion Systems for ion mobility separation technology called Structures for Lossless Ion Manipulation (SLIM) on its Q-TOF mass spectrometers.

The global clinical communication and collaboration market is on the cusp of significant growth, with revenue projected to reach $4.8 billion by 2029, growing at an impressive CAGR of 13.2% from 2024 to 2029. This expansion is driven by the numerous advantages these solutions offer in enhancing patient care and safety, the increasing demand for cost-containment measures within healthcare delivery systems, and the rising adoption of big data and mHealth tools.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=118830286

Key Drivers and Opportunities

The primary driver for the market’s growth lies in the ability of clinical communication solutions to streamline the flow of real-time health data, enabling continuous patient monitoring and minimizing errors through seamless communication among healthcare teams. The integration of these solutions with Electronic Health Records (EHRs) further enhances their value, facilitating informed decision-making and coordinated care efforts.

Emerging markets present significant opportunities for the clinical communication and collaboration industry. The growing adoption of EHRs in these regions, coupled with advancements in mobile applications, cloud computing, and interoperability, is expected to fuel market expansion.

Challenges and Restraints

However, the market also faces challenges, particularly in terms of data security. Healthcare organizations must navigate the delicate balance between enabling efficient communication and safeguarding sensitive patient information. High-profile data breaches and the increasing interconnectedness of healthcare IT infrastructure underscore the importance of robust security measures.

Another restraint is the substantial investment required to build and maintain the necessary IT infrastructure. The financial burden associated with implementing and maintaining advanced communication technologies can be a barrier for smaller healthcare facilities with limited budgets.

Market Segmentation and Key Players

The clinical communication and collaboration market is segmented based on platform, component, deployment mode, application, end-user, and region. In 2023, the software segment accounted for the largest market share, driven by the increasing adoption of digitalization and technological advancements in healthcare. Cloud-based deployment models are expected to register the highest growth during the forecast period, offering enhanced accessibility, scalability, and cost-effectiveness.

Hospitals and clinics dominate the end-user segment, attributing to their increasing adoption of software solutions for improved patient care. North America currently holds the largest share of the market, while the Asia Pacific region is projected to grow at the highest CAGR due to its rapidly expanding healthcare landscape and supportive government initiatives.

Prominent players in the market include Avaya LLC, Oracle, Cisco Systems, Inc., Microsoft Corporation, Baxter International (Hillrom), and several others. These companies are at the forefront of innovation, driving the development of advanced clinical communication and collaboration solutions.

Cisco Systems, Inc. (US)

Cisco has continued to enhance its overall clinical communication and collaboration solutions with a significant focus on Al, which it calls cognitive collaboration. One of Cisco’s biggest moves this past year was its launch of a unified client that brings Cisco Webex (cloud collaboration) and its on- premises Cisco Unified Communications Manager capabilities together as one common user experience. Cisco’s CC&C portfolio is led by its Cisco Webex Collaboration cloud, which combines Webex video meetings, calling, team collaboration, and collaboration devices. Cisco also offers Webex Contact Center, which is a cloud contact center service integrated with the Webex UCC suite

Oracle (US)

Oracle is one of the leading provider of HCIT solutions and support & maintenance services. The company Cerner’s device connectivity solutions allow interoperability between medical devices, healthcare applications and the EHR, regardless of vendor, enabling clinicians to streamline their workflows and focus more on their patients. Oracle’s geographical operations span across North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. Along with understanding customer needs, the company has maintained robust relationships with existing suppliers, thus contributing to its strong supply chain in the market. Thus, leveraging its extensive expertise in database management, cloud computing, and enterprise applications, Oracle has developed robust communication and collaboration solutions.

The Future of Healthcare Communication

As healthcare organizations increasingly recognize the critical role of effective communication and collaboration in delivering high-quality patient care, the clinical communication and collaboration market is poised for significant growth. With the integration of cutting-edge technologies and the ongoing need to streamline healthcare processes, this industry is set to revolutionize the way healthcare professionals interact and collaborate, ultimately leading to better patient outcomes and enhanced safety.

https://www.prnewswire.com/news-releases/clinical-communication–collaboration-market-worth-4-8-billion–marketsandmarkets-302110826.html

https://www.globenewswire.com/news-release/2024/04/25/2869631/0/en/Clinical-Communication-Collaboration-Market-is-Expected-to-Reach-4-8-billion-MarketsandMarkets.html

The global mental health screening market is on the cusp of substantial expansion, with revenue expected to surpass $1.8 billion by 2029, growing at an impressive CAGR of 12.2% from 2023 to 2029. In 2023, the market size was estimated at $0.9 billion.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=198516770

Key Drivers and Trends:

The market’s growth is propelled by rising awareness of mental health issues, a heightened focus on remote monitoring solutions, and technological advancements in screening tools. Surveys indicate a notable shift in societal attitudes, with 82% of Americans now considering mental health as crucial as physical well-being, up from 68% in 2018.

However, stigma surrounding mental illness persists as a restraining factor, with 44% of Americans experiencing discrimination due to their condition. Limited awareness about available screening resources also contributes to underutilization.

Social media platforms present a significant opportunity for increasing adoption of screening tools. The Trevor Project found that 76% of LGBTQ+ youth use social media to access mental health information and support. Harnessing social media’s reach can normalize discussions and encourage help-seeking behaviors.

Concerns about the accuracy and validity of screening tools pose a challenge. Studies have found variability in the performance of popular apps, emphasizing the need for rigorous validation processes.

Market Segmentation Insights:

Among psychiatric disorders, attention deficit hyperactivity disorder (ADHD) dominates the market in 2022 due to growing awareness and diagnoses.

Self-reported questionnaires and surveys are expected to exhibit the highest growth rate from 2024 to 2029, driven by their wide availability, affordability, and multilingual formats.

The online platforms segment is poised for the fastest growth, attributable to the availability of personalized assessments.

Regional Analysis:

North America held the largest market share in 2023, supported by increasing demand for mental health services, healthcare reforms, and government funding in the region.

Prominent Players:

Key players in the mental health screening market include Proem Behavioral Health, SonderMind Inc., Riverside Community Care, Headspace Health, Quartet Health, Inc., and others.

Recent Developments:

• SonderMind acquired Total Brain in November 2023 to expand its offerings.
• Ellipsis Health, Inc. partnered with Augmedix in October 2023 to introduce automated mental health screenings.
• Quartet Health, Inc. acquired InnovaTel Telepsychiatry in December 2021 to accelerate high-quality mental healthcare delivery.

The mental health screening market is poised for significant growth, driven by rising awareness, technological advancements, and the potential of social media. While challenges like stigma and accuracy concerns persist, the market’s trajectory indicates a promising future in addressing the critical issue of mental well-being.

https://www.prnewswire.com/news-releases/mental-health-screening-market-worth-1-8-billion–marketsandmarkets-302081019.html

https://www.globenewswire.com/news-release/2024/03/26/2852343/0/en/Mental-Health-Screening-Market-is-Expected-to-Reach-1-8-billion-MarketsandMarkets.html

The global tissue engineering market is projected to expand from $4.4 billion in 2023 to $8.9 billion by 2028, representing a strong CAGR of 15.3%. Key growth drivers include the rising need for advanced regenerative medicines to treat chronic and degenerative diseases, as well as increasing incidence of traumatic injuries from accidents.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=34135173

While high treatment costs currently restrain market growth, exciting technological advancements like 3D bioprinting, organ-on-chip technology, and Quantum Magnetic Resonance Therapy (QMRT) present attractive future growth opportunities. Traditional organ transplants remain a more cost-effective alternative currently and are a challenge the industry must overcome.

The tissue engineering ecosystem involves hospitals, clinics, technology providers, regulatory bodies, and collaborative networks all working together to advance tissue engineering solutions. Scaffold products, especially synthetic and biological materials like collagen and hydrogels, are the fastest growing segment. Orthopedics and musculoskeletal disorders are the dominant application area.

Geographically, North America leads the tissue engineering market, followed by Europe, driven by a thriving healthcare sector, intensive research activities, and rising degenerative disease rates. Key players include Organogenesis, AbbVie, Baxter, BD, Integra Lifesciences, and Johnson & Johnson, among others.

Recent developments include new product launches like MIMEDX’s placental-based allograft EPIEFFECT, Teijin’s SYNFOLIUM cardiovascular patch, and Integra’s SurgiMend collagen matrix, as well as AbbVie’s acquisition of Allergan to expand into new therapeutic areas. The future of tissue engineering looks very promising as the field advances.

AbbVie Inc. (US)

AbbVie Inc. is a research-based biopharmaceutical company operating in different areas, including oncology, immunology, neuroscience, aesthetics, and eye care. The company has a strong geographic presence across 70 countries with a broad range of distribution channels across 175 countries. AbbVie Inc. adopted strategic approaches such as acquisitions, partnerships, and collaborations to strengthen its geographic presence. For instance, in May 2020, AbbVie Inc. acquired Allergan plc. The acquisition aims to expand the long term growth of the company in therapeutic categories. Allergan offers new growth opportunities through its leading brands of tissue engineering products such as AlloDerm and Strattice.

Baxter (US)

Baxter (US) is a leading healthcare solution provider with a wide range of products under pharmaceutical injectables, diagnostics, anesthetics, adhesion prevention, hemostats & sealants, tissue repair technology, and bone repair technology. The company has strong distribution channels across 100 countries. Baxter focuses on the expansion of the product portfolio through product approvals and product launches. For instance, in July 2020, Baxter International received clearance from the US FDA for Altapore Shape Bioactive Bone Graft, which is designed to enhance bone growth and help achieve fusion in surgeries involving the skeletal system. The product is easy to mold and can be used as a standalone bone graft substitute or as an autograft extender to fill bony voids or gaps in the skeletal system, including in the pelvis, extremities, and posterolateral spine, which are surgically created or result from trauma.

Integra Lifesciences (US)

Integra Lifesciences is a leading provider of neurological solutions, regenerative technologies, and surgical instrumentation. The company offers a wide range of products for hemorrhagic stroke, multiple disease states, traumatic brain injury, and other neurological conditions. The company has a strong global presence in 130 countries. Integra Lifesciences aims to expand its customer base by adopting various strategic alliances such as partnerships, acquisitions, and collaborations. For instance, in January 2021, Integra Lifesciences acquired Acell Inc. ACell is a regenerative medicine company known for its proprietary porcine urinary bladder matrix platform technology, MatriStem UBM, which aligns with Integra’s focus on regenerative medicine and tissue technologies.

The global base editing market is experiencing remarkable growth, fueled by the rising prevalence of genetic diseases and the urgent need for precise gene editing technologies. Valued at $270 million in 2023, this market is projected to reach $549 million by 2028, expanding at an impressive compound annual growth rate (CAGR) of 15.2%.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=21238371

Driving this growth is the increasing recognition of the role genetic mutations play in various diseases. As rare and orphan diseases become more prevalent, the demand for innovative therapies has skyrocketed, propelling base editing to the forefront of rare disease research and treatment.

Base editing, a cutting-edge technology, offers a more precise alternative to traditional CRISPR-Cas9 methods, potentially minimizing off-target effects. However, ethical and safety concerns remain a significant barrier to its widespread adoption. The inadvertent modifications to DNA can have detrimental consequences, necessitating a vigilant focus on enhancing the safety and specificity of these techniques.

Nonetheless, the expanding pipeline of gene therapy products and regulatory approvals present significant opportunities for the base editing market. With over 1,000 gene therapy products in development, including over 200 in clinical trials, the potential for transformative breakthroughs in personalized medicine and the treatment of previously incurable diseases is promising.

One of the primary challenges facing the industry is the issue of off-target effects – unintentional modifications to DNA sequences other than the intended target. Researchers are continually working to improve the design and engineering of base editors to reduce this risk and enhance precision.

The base editing market ecosystem comprises a diverse array of stakeholders, including pharmaceutical and biotechnology companies, academic and research institutes, contract research organizations, reagent and kit suppliers, technology providers, data management and analysis providers, regulatory authorities, and collaborative networks. Their interactions and collaborations drive the advancement of base editing products and services, enhance drug discovery processes, and develop new therapeutics.

Geographically, North America currently dominates the base editing market, thanks to its well-established infrastructure for funding research and development initiatives and a supportive regulatory environment for life sciences innovation.

Key players in the global base editing market include Danaher Corporation, Merck KGaA, Revvity, Maravai LifeSciences, GenScript, Beam Therapeutics, Intellia Therapeutics, Inc., Cellectis, ElevateBio, Creative Biogene, Bio Palette Co., Ltd, Addgene, Synthego, EdiGene, Inc., Shape TX, Pairwise, ProQR Therapeutics, QI-Biodesign, KromaTiD, Inc., and GenKOre.

As the base editing market continues to grow, it holds the potential to revolutionize the treatment of genetic disorders and usher in a new era of personalized medicine, where precision and efficacy are at the forefront of therapeutic interventions.

The global transdermal patches market is poised for significant expansion in the coming years, projected to grow from $6.2 billion in 2023 to $8.0 billion by 2029 at a compound annual growth rate (CAGR) of 4.5%. This burgeoning market is driven by several key factors, including the rising prevalence of chronic diseases, the increasing adoption of analgesic patches, technological advancements in transdermal patch development, and a shift away from traditional injections toward more convenient and patient-friendly transdermal delivery systems.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=190809043

One of the primary driving forces behind this growth is the growing popularity of analgesic patches for pain management. These patches offer a localized and controlled release of painkillers through the skin, reducing the risk of systemic adverse effects associated with oral medications. Patients with chronic pain disorders are increasingly turning to analgesic patches for their ease of administration, prolonged wear time, and improved compliance.

However, the market’s progress is tempered by challenges such as drug failures, transdermal drug delivery system recalls, and rising healthcare facility costs. Ensuring consistent drug delivery, minimizing adverse reactions, and implementing stringent quality control measures during manufacturing are crucial to overcoming these obstacles.

Collaborations between pharmaceutical companies and drug delivery firms present a significant opportunity for innovation and growth in the transdermal patch market. By combining their respective expertise in drug discovery, formulation, and cutting-edge delivery technologies, these partnerships can lead to the development of advanced transdermal patches with improved adherence, better drug release profiles, and fewer side effects.

Nonetheless, technical barriers related to skin irritation and permeability remain a challenge. Achieving the optimal balance between effective drug penetration and minimizing skin irritation requires careful formulation considerations and innovative approaches to enhance permeability while maintaining skin integrity.

The market is further segmented by patch type, adhesive type, application, distribution channel, and end-user. The multi-layer drug-in-adhesive segment is expected to hold the largest share due to its innovative design and precise drug release control capabilities. Additionally, the Asia-Pacific region is projected to experience the highest CAGR, driven by the rising prevalence of chronic diseases, increasing healthcare awareness, and government initiatives promoting access to advanced medical technologies.

Key players in the transdermal patches market include Johnson & Johnson, Viatris Inc., Hisamatsu Pharmaceuticals Co. Ltd., UCB S.A., Boehringer Ingelheim International GmbH, Endo International plc., Teva Pharmaceutical Industries Ltd., Agile Therapeutics, Bayer AG, Nitto Denko Corporation, and Cipla Inc., among others.

As the transdermal patch market continues to evolve, addressing technical challenges, fostering industry collaborations, and meeting the growing demand for convenient and effective drug delivery solutions will be crucial for sustained growth and innovation in this dynamic sector.

The global single-use bioprocessing market is experiencing explosive growth, projected to skyrocket from $8.2 billion in 2021 to $20.8 billion by 2026 at an impressive 20.5% compound annual growth rate (CAGR). This surge is fueled by the increasing demand for biopharmaceuticals, driven by an aging global population more susceptible to chronic conditions.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231651297

Single-use bioprocessing systems offer numerous advantages over traditional stainless-steel equipment, including greater energy efficiency, reduced water usage, smaller footprints, lower costs, quicker implementation, and diminished risk of cross-contamination. While concerns exist around extractables, leachables, and waste disposal, emerging markets in Asia like China and India present lucrative opportunities for this technology.

Major players like Sartorius, Danaher’s Cytiva, Thermo Fisher, and Merck are making massive investments to expand single-use bioprocessing capabilities and meet soaring demand for biologics and vaccines. Thermo Fisher alone invested over $475 million in 2020 to bolster its St. Louis facilities.

Sartorius Stedim Biotech held the leading position in the single-use bioprocessing market in 2020. Sartorius focuses on strengthening its position in the market by adopting organic and inorganic strategies such as product launches and expansions. During the past three years, Sartorius Stedim Biotech launched SUB systems such as BIOSTAT STR Generation 3 Single-Use Bioreactor, BIOSTAT RM TX Single-Use Bioreactor, and BIOSTAT STR. In 2019, Sartorius acquired Danaher’s Life Science portfolio, which is complementary to the portfolio of Sartorius’s laboratory and bioprocess business. In 2019, the company also expanded their operations in Puerto Rico.

Thermo Fisher Scientific is the second-largest player in the single-use bioprocessing market. Thermo Fisher Scientific operates in the single-use bioprocessing market through the life science solutions business segment. To further increase its share in the single-use bioprocessing market, the company focuses on growth strategies such as acquisitions and expansion. From 2019 to 2021, the company expanded its business in the US. The company also made investments worth ~USD 650 million from 2019 to 2021 to enhance their single-use bioprocessing capabilities and increase their market share.

The single-use media bags and containers segment currently dominates the market, driven by their widespread use across biomanufacturing processes. However, demand is strong across all application areas including filtration, storage, cell culture, mixing, and purification.

As biopharmaceutical production continues ramping up globally, the future looks extremely bright for flexible, cost-effective single-use bioprocessing solutions to unlock new manufacturing efficiencies and accelerate delivery of life-saving treatments.

Recent Developments of Single Use Bioprocessing Industry:

• In March 2020, Danaher acquired the Biopharma business from General Electric Company’s Life Sciences division. The business is called Cytiva, and is a standalone operating company within Danaher’s Life Sciences segment.
• In September 2020, Thermo Fisher Scientific invested more than USD 475 million in new capabilities at its St. Louis site to expand biologics development and manufacturing, cell and gene therapy capabilities, and drug product development capabilities.